Stimulant Oxytocin Study

• Status: Completed
• Trial end date: 2020-02-14
• Target enrollment: 0
• Participant gender: All

Summary

This study will investigate the effects of intranasal administration of oxytocin, a social neuropeptide, on reducing stimulant use, enhancing therapeutic engagement, and susceptibility to stress-induced relapse in Veterans with stimulant use disorders and enrolled in opioid replacement therapy (ORT) program for co-occurring opioid use disorder (OUD).

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: VA Office of Research and Development
• Treatments: Cocaine; Methadone; Oxytocin

Criteria

Inclusion Criteria:

1. At least 18 years old

2. Enrolled as a patient who at the SFVAMC Opioid Treatment Program or the Oakland Behavioral Health Clinic Opioid Treatment Program

3. Stable dose of opioid replacement therapy for at least 2 consecutive weeks

4. Veteran

5. One documented urine toxicology screen positive for stimulants in the past 12 months.

Exclusion Criteria:

1. Severe neuropsychological disorder

2. Suicidal or homicidal ideation within the past 90 days or a suicide attempt in the past 6 months

3. Hemodialysis, unless participant can produce urine samples weekly

4. Sensitivity to methylparaben or propylparaben

5. Positive urine pregnancy test or women of childbearing age not practicing effective means of non-hormonal birth control

6. Chronic nasal obstruction, discharge, or bleeding